Status:
NOT_YET_RECRUITING
EVOLV-Rx VA: Evaluating Opportunities to Decrease Low-Value Prescribing in Community Living Centers
Lead Sponsor:
VA Office of Research and Development
Conditions:
Low-Value Care
Eligibility:
All Genders
65+ years
Phase:
NA
Brief Summary
The investigators developed EVOLV-Rx (Evaluating Opportunities to Decrease Low-Value Prescribing), a novel clinical support tool to detect 18 evidence-based and clinically useful low-value prescribing...
Detailed Description
Background: More than half of Veterans aged 65 years who reside in Community Living Centers (CLCs) are subject to low-value prescribing, placing them at increased risk of adverse drug events, hospital...
Eligibility Criteria
Inclusion
- Veterans aged 65+ admitted to a participating VISN 4 CLC at the time of the required medication review.
Exclusion
- Veterans receiving hospice care, as the discontinuation of medications in EVOLV-Rx (e.g., benzodiazepines) may result in undue discomfort.
- During both the usual care and intervention period of the study, the study coordinator will query the EVOLV-Rx dashboard weekly.
- The coordinator will ensure the presence of inclusion/exclusion criteria via chart review and using the EVOLV-Rx dashboard, they will then flag the patient if they are receiving hospice care and should be excluded from the study.
Key Trial Info
Start Date :
September 1 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2028
Estimated Enrollment :
1161 Patients enrolled
Trial Details
Trial ID
NCT07166107
Start Date
September 1 2026
End Date
December 31 2028
Last Update
October 21 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Philadelphia, Pennsylvania, United States, 19104-4551
2
VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA
Pittsburgh, Pennsylvania, United States, 15240